Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Xiangsheng Medical (688358), indicating a decline in revenue and profit for the first three quarters of 2025 compared to the previous year [2] - As of December 23, 2025, Xiangsheng Medical's stock closed at 30.12 yuan, down 1.21%, with a turnover rate of 0.53% and a trading volume of 5,928 hands, amounting to a transaction value of 17.89 million yuan [1] - The company reported a main revenue of 343 million yuan for the first three quarters of 2025, a year-on-year decrease of 5.27%, and a net profit attributable to shareholders of 93.92 million yuan, down 4.56% year-on-year [2] Group 2 - In the third quarter of 2025, the company achieved a single-quarter main revenue of 107 million yuan, a decline of 6.68% year-on-year, while the single-quarter net profit attributable to shareholders increased by 41.95% to 24.22 million yuan [2] - The company has a debt ratio of 11.24% and reported investment income of 3.01 million yuan, with financial expenses of -16.53 million yuan and a gross profit margin of 59.82% [2] - Over the last 90 days, three institutions have given buy ratings for Xiangsheng Medical, indicating positive sentiment among analysts [3]

资金流向 12月22日主力资金净流入344.72万元；游资资金净流出191.0万元；散户资金净流出153.72万元。 公司公告汇总 无锡祥生医疗科技股份有限公司2025年第三次临时股东会会议资料 无锡祥生医疗科技股份有限公司拟以2025年前三季度实现的归属于上市公司股东净利润为基础，向全体 股东每10股派发现金红利3元（含税），分配总额以权益分派股权登记日登记的总股本扣减回购专用账 户股份数为基数计算，不进行资本公积转增股本和送红股。该方案已由董事会及相关委员会审议通过， 提请股东大会审议。 截至2025年12月22日收盘，祥生医疗(688358)报收于30.49元，下跌0.2%，换手率1.12%，成交量1.25万 手，成交额3862.65万元。 当日关注点 交易信息汇总 祥生医疗股东减持计划时间届满暨减持股份结果公告 本次减持计划实施前，祥鼎投资持有祥生医疗4,704,000股，占总股本4.20%；上海御德持有1,679,956 股，占总股本1.50%；祥鹏投资持有1,344,000股，占总股本1.20%。2025年8月29日，公司披露减持计 划，上述股东拟通过集中竞价或大宗交易方式减持部分股份。截至202 ...

| 股东名称 | 无锡祥雕投资企业有限合伙) | | --- | --- | | 减持十双百次变露日期 | 2025年8月29日 | | 减得数量 | OR | | 国际视觉 | 2025年9月22日 -2025年12月21日 | | 减持方式及对应减持股份 | 师中变价2应控,0报 大家交易减持,0股 | | 减持价格区间 | 0.00-0.00元/投 | | 城市石安新 | 0.00元 | | 成特定成開及 | 来完成:1,176,000發 | | 减持比例 | 0.00% | | 既计划或接到比例 | 不能付 1.05% | | 当前特股数量 | 4,704,000원 | | 新闻特股北例 | 4.2012 | | 股东名称 | 无锡祥鼎投资企业(有限合伙) | | | --- | --- | --- | | 股东身份 | 我我在,其我人及一就行动人 原模特系统计算案 或事,因非基因为因人的 | VHOW Deve | | | 试值:594以下股东 | | | 持投放量 | 4.704.000 R | | | 产能化制 | 4.20% | | | ■前持投股份来源 | IPO 前球得:3,024,000 ...

南财智讯12月21日电，祥生医疗公告，公司股东祥鼎投资、上海御德、祥鹏投资此前披露的减持计划期 间为2025年9月22日至2025年12月21日，拟分别减持不超过1.05%、0.37%、0.30%的股份。截至2025年 12月21日，上述减持计划时间届满，三位股东均未实施减持，实际减持比例为0.00%。目前，祥鼎投资 仍持有公司4.20%股份，上海御德持有1.50%股份，祥鹏投资持有1.20%股份。 ...

截至发稿，祥生医疗市值为34亿元。 每经头条（nbdtoutiao）——大洗牌！AI手机大战开启，豆包率先放大招！苹果、谷歌"慢半拍"？业 内：苹果是"最保守的大玩家" 每经AI快讯，祥生医疗（SH 688358，收盘价：30.55元）12月21日晚间发布公告称，近日，公司收到减 持主体的告知函，截至2025年12月21日，上述减持计划时间已届满，在减持计划期限内，公司股东祥鼎 投资、上海御德、祥鹏投资未减持公司股份。 2024年1至12月份，祥生医疗的营业收入构成为：医疗器械行业占比99.88%，其他业务占比0.12%。 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 （记者 曾健辉） ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-051 无锡祥生医疗科技股份有限公司 股东减持计划时间届满暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东及董监高持有的基本情况 本次减持计划实施前，无锡祥生医疗科技股份有限公司（以下简称"祥生医 疗"或"公司"）股东无锡祥鼎投资企业（有限合伙）（以下简称"祥鼎投资"）持有 公司股份 4,704,000 股，占公司总股本的 4.20%；股东上海御德科技有限公司（以 下简称"上海御德"）持有公司股份 1,679,956 股，占公司总股本的 1.50%；股东 无锡祥鹏投资企业（有限合伙）（以下简称"祥鹏投资"）持有公司股份 1,344,000 股，占公司总股本的 1.20%。 上述股份均为无限售流通股，来源于公司首次公开发行前取得的股份以及公 司实施资本公积转增股本取得的股份，涉及公司首次公开发行前取得的股份已于 2022 年 12 月 3 日解除限售并上市流通。 减持计划的实施结果情况 2025 年 8 月 ...

无锡祥生医疗科技股份有限公司 2025 年第三次临时股东会会议资料 证券代码：688358 证券简称：祥生医疗 无锡祥生医疗科技股份有限公司 2025 年第三次临时股东会 会议资料 二〇二五年十二月 现场要求提问的股东及股东代理人，应当按照会议的议程举手示意，经会 议主持人许可后方可提问。有多名股东及股东代理人同时要求提问时，先举手 者先提问；不能确定先后时，由主持人指定提问者。 1 无锡祥生医疗科技股份有限公司 2025 年第三次临时股东会会议资料 无锡祥生医疗科技股份有限公司 2025 年第三次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证 会议的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股东会规则》以及《无锡祥生医疗科技股份有限公司章程》《无锡 祥生医疗科技股份有限公股东会议事规则》等相关规定，无锡祥生医疗科技股 份有限公司（以下简称"公司"）特制定本次股东会会议须知： 一、为确认出席会议的股东或其代理人或其他出席者的出席资格，会议工 作人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次会议的严肃性和正常 ...

Group 1 - The company, 瑞奇智造, announced that it will hold its second extraordinary general meeting of shareholders on December 18, 2025 [2] - The agenda includes a proposal to change the accounting firm [2]

Group 1: China Civil Aviation Information Network (00696) - The company is a leading GDS provider globally and the largest in China, with a global market share of approximately 28% and a domestic market share of about 95% [10] - The company's performance is highly correlated with the growth of the civil aviation industry, with expected flight bookings reaching 732 million in 2024, surpassing the 2019 peak [10] - The launch of the "official direct sales platform" in July 2025 positions the company to enter the trillion-yuan OTA market, aiming to reduce reliance on traditional OTAs [10] - The company is projected to achieve net profits of 2.21 billion, 2.43 billion, and 2.65 billion yuan from 2025 to 2027, with a maintained "buy" rating based on recovery in the civil aviation sector [10] Group 2: Xiangsheng Medical (688358) - Xiangsheng Medical has focused on ultrasound technology since its establishment in 1996, holding over 400 intellectual property rights and offering a comprehensive range of ultrasound products [11] - The company aims to leverage its "portable + intelligent" advantage, with products like SonoFamily series that include high-end and portable ultrasound devices, enhancing its competitive edge [11] - The company is expected to achieve revenues of 517 million, 620 million, and 744 million yuan from 2025 to 2027, with net profits projected at 146 million, 182 million, and 229 million yuan, respectively, maintaining a "buy" rating [13] Group 3: CIMC Enric (03899.HK) - CIMC Enric is a clean energy equipment platform under CIMC, focusing on LNG transportation, storage, and processing, with a projected net profit CAGR of 17% from 2020 to 2024 [13] - The company has a robust order backlog of 30.8 billion yuan, with 27.3 billion yuan in clean energy equipment orders, benefiting from the LNG market's growth [14] - The company is expected to achieve net profits of 1.13 billion, 1.47 billion, and 1.76 billion yuan from 2025 to 2027, with a "buy" rating based on a 29% upside potential from its current valuation [15] Group 4: PVA Industry (皖维高新 600063) - The company has established a comprehensive PVA industrial chain, with a focus on cost advantages and long-term growth potential, aiming to expand into high-value new materials [23] - The company is positioned to benefit from a recovery in demand for PVA products, with a projected increase in production capacity and profitability in the coming years [23] - The company is expected to achieve revenues of 8.064 billion, 8.881 billion, and 9.768 billion yuan from 2025 to 2027, with net profits projected at 473 million, 622 million, and 862 million yuan, respectively, maintaining an "overweight" rating [25] Group 5: Social Services Industry - The introduction of spring and autumn holidays has stimulated tourism demand, with significant increases in travel and spending during these periods [26] - The winter "snow holiday" policy has also contributed to the recovery of the ice and snow tourism industry, with various incentives driving participation [26] - The overall service consumption is expected to benefit from government policies aimed at boosting demand, with a focus on tourism and related sectors [27]

Core Viewpoint - Xiangsheng Medical (688358) has completed the grant registration of its 2025 restricted stock incentive plan, issuing 150,000 shares at a price of 16.50 yuan per share, which will not affect the company's control [1]. Group 1: Stock Performance - As of December 15, 2025, Xiangsheng Medical's stock closed at 29.82 yuan, up 0.81% from the previous trading day, with a total market capitalization of 3.344 billion yuan [1]. - The stock opened at 29.58 yuan, reached a high of 30.18 yuan, and a low of 29.40 yuan, with a trading volume of 22.3845 million yuan and a turnover rate of 0.67% [1]. Group 2: Incentive Plan Details - The company granted 150,000 restricted shares to 16 incentive recipients, with the stock sourced from a buyback of 148,924 shares and a directed issuance of 1,076 shares [1]. - The total share capital increased from 112,124,537 shares to 112,125,613 shares, with no change in control of the company [1]. - The lock-up period for the shares is set for 12 months and 24 months, with 50% of the shares being released from the lock-up in two phases [1].